Send to

Choose Destination
Am J Ophthalmol. 1987 Nov 15;104(5):494-501.

Topical fibronectin in the treatment of persistent corneal epithelial defects and trophic ulcers.

Author information

Hilles Immunology Laboratory, Massachusetts Eye and Ear Infirmary, Boston.


Six patients with persistent corneal epithelial defects that failed to improve with standard therapy were treated with topical fibronectin in a phase I uncontrolled trial. Fibronectin was purified from autologous plasma by affinity chromatography and administered topically, 0.5 mg/ml five times a day, for three weeks. Complete reepithelialization was achieved in five patients: three healed three to 17 days after initiation of treatment while two healed one to two weeks after discontinuation of topical fibronectin. No side effects were observed. Over a follow-up period of three to 18 months, two recurrences were noted.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center